BioNexus Gene Lab Corp. Launches VitaGuard MRD Platform Across Southeast Asia
I'm PortAI, I can summarize articles.
BioNexus Gene Lab Corp. has launched its VitaGuard™ Minimal Residual Disease (MRD) platform across Southeast Asia, aiming to enhance precision diagnostics and replace outdated cancer monitoring systems. The company has established Fidelion Diagnostics Pte. Ltd. for managing intellectual property and commercialization outside China, and is recruiting staff for this initiative. Additionally, BioNexus is preparing for market entry with a regional partner and upgrading global patent filings to support the platform's growth.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments